GRI Bio logo
GRI Bio
GRI | NASDAQ
Chart Builder DCF Calculator
$1.40
-$0.30 (-17.65%)
At close: Nov 16, 2026, 4:00 PM ET
$1.40
$0.00 (+0.31%)
After-hours: Nov 16, 2026, 7:46 PM ET

GRI Bio Company Profile

Company profile explained

Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Key Executives

Name Position
W. Marc Hertz Co-Founder, Chief Executive Officer, President & Director
Leanne Kelly Chief Financial Officer & Corporate Secretary
Albert Agro Co-Founder & Chief Medical Officer
Vipin Kumar Co-Founder & Chief Scientific Officer

Latest SEC Filings

Date Type Title
Sep 28, 2026 ARS Filing
Sep 28, 2026 DEF 14A Filing
Sep 08, 2026 8-K Current Report
Aug 14, 2026 10-Q Quarterly Report
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
View All SEC Filings ➞
GRI Bio
GRI Bio logo
Country United States
IPO Date Feb 10, 2021
Industry Biotechnology
Sector Healthcare
Employees 4
CEO W. Marc Hertz

Contact Details

2223 Avenida de la Playa La Jolla, California 92037 United States

Stock Details

Ticker Symbol GRI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001824293
CUSIP Number 3622AW502
ISIN Number US3622AW5029
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.